Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Proof-of-Concept Study to Evaluate the Effects of NDX-1017 to Treat Alzheimer's Disease

Trial Profile

A Phase 2 Proof-of-Concept Study to Evaluate the Effects of NDX-1017 to Treat Alzheimer's Disease

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 11 Apr 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NDX 1017 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Athira Pharma
  • Most Recent Events

    • 11 Apr 2019 According to a M3 Biotechnology media release, this study is planned to start in 2019.
    • 11 Apr 2019 According to a M3 Biotechnology media release, the companys phase 2 trials including this trial will be supported in part by the Alzheimer's Association through its PART THE CLOUD to RESCUE Program.
    • 11 Apr 2019 According to a M3 Biotechnology media release, the company has changed its name from M3 Biotechnology to Athira Pharma, Inc.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top